Japanese Drug Makers, Institute Develop Longer-Lasting Cultured Cells
This article was originally published in PharmAsia News
Several Japanese drug makers and Japan's National Institute of Health Sciences have developed a new technique for preserving cultured cells for drug compatibility evaluation. Researchers from Astellas Pharma, Chugai Pharmaceutical, Kyowa Hakko Kogyo, Mitsubishi Tanabe Pharma, Nippon Shinyaku and Sanofi-Aventis KK joined the institute in the development. The technique they came up with extends the effective life of enzymes used by cells to metabolize drugs, eliminating the need to prepare and maintain new cell cultures for drug development efforts. (Click here for more - a subscription may be required
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.